Regeneron Secures $4.5 Billion Worth of Contracts from the US for Combating COVID-19

by GeneOnline
Share To

By Vicky Su

On July 7th, 2020, Regeneron Pharmaceuticals, Inc. announced that the Trump administration has awarded them a $4.5 billion contract to manufacture and supply REGN-COV2, an investigational antibody cocktail for COVID-19.

REGN-COV2 is a novel double-antibody drug cocktail developed by Regeneron. The two virus-neutralizing antibodies in the cocktail can recognize and bind to the receptor of the critical spike protein that SARS-COV-2 uses to enter cells. Similar to the cocktail therapy concept used for HIV prevention, the double-antibody could protect against viral escape and achieve antiviral effects.

In mid-June 2020, Regeneron launched the first REGN-COV2 clinical trial, aiming to test the ability to treat and prevent coronavirus. Four cohorts were recruited; hospitalized and non hospitalized symptomatic COVID-19 patients, as well as uninfected people such as healthcare workers with high exposure risk, and uninfected people exposed to COVID-19 (such as the patient’s roommates).

On July 6th, the company announced the initiation of its late-stage trials. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent COVID-19, which is expected to recruit 2,000 uninfected subjects in close contact with COVID-19 patients. The trial will be conducted in 100 different locations.

REGN-COV2 has also moved to the Phase 2/3 section that evaluates the cocktail’s ability to treat hospitalized and non-hospitalized (or “ambulatory”) patients with COVID-19. The trial will recruit about 1,850 inpatients and 1,050 non-inpatients (e.g., outpatients), and conducted in approximately 150 regions in the United States, Brazil, Mexico, and Chile.

Besides, these ongoing clinical trials are also aiming to identify the most suitable dose. Regeneron is expected to release the drug by the end of the summer. The US government has promised that if the drug notches an emergency FDA authorization for both the prevention and treatment o COVID-19, it will be distributed to the people free of charge.

“This agreement with Regeneron is the first of several Operation Warp Speed awards to support potential therapeutics through large scale manufacturing, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar.

Editor: Sherry Hsiao

Related Article: COVID-19: Discovery of New Spike Protein Neutralizing Antibody Reveals Promising Drug Target



© All rights reserved. Collaborate with us: [email protected]
Related Post
Rising Bird Flu Cases in Cattle and Humans Drive Global Efforts in Vaccination, Genetic Monitoring, and Surveillance
Sanofi and Regeneron’s Dupixent Approved as First-in-World Treatment For Uncontrolled COPD
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top